Unknown

Dataset Information

0

Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer.


ABSTRACT: The role of intestinal human pregnane X receptor (PXR) in colon cancer was determined through investigation of the chemopreventive role of rifaximin, a specific agonist of intestinal human PXR, toward azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colon cancer. Rifaximin treatment significantly decreased the number of colon tumors induced by AOM/DSS treatment in PXR-humanized mice, but not wild-type or Pxr-null mice. Additionally, rifaximin treatment markedly increased the survival rate of PXR-humanized mice, but not wild-type or Pxr-null mice. These data indicated a human PXR-dependent therapeutic chemoprevention of rifaximin toward AOM/DSS-induced colon cancer. Nuclear factor ?-light-chain-enhancer of activated B cells-mediated inflammatory signaling was upregulated in AOM/DSS-treated mice, and inhibited by rifaximin in PXR-humanized mice. Cell proliferation and apoptosis were also modulated by rifaximin treatment in the AOM/DSS model. In vitro cell-based assays further revealed that rifaximin regulated cell apoptosis and cell cycle in a human PXR-dependent manner. These results suggested that specific activation of intestinal human PXR exhibited a chemopreventive role toward AOM/DSS-induced colon cancer by mediating anti-inflammation, antiproliferation, and proapoptotic events.

SUBMITTER: Cheng J 

PROVIDER: S-EPMC4244584 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer.

Cheng Jie J   Fang Zhong-Ze ZZ   Nagaoka Kenjiro K   Okamoto Minoru M   Qu Aijuan A   Tanaka Naoki N   Kimura Shioko S   Gonzalez Frank J FJ  

The Journal of pharmacology and experimental therapeutics 20141002 3


The role of intestinal human pregnane X receptor (PXR) in colon cancer was determined through investigation of the chemopreventive role of rifaximin, a specific agonist of intestinal human PXR, toward azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colon cancer. Rifaximin treatment significantly decreased the number of colon tumors induced by AOM/DSS treatment in PXR-humanized mice, but not wild-type or Pxr-null mice. Additionally, rifaximin treatment markedly increased the survival rate  ...[more]

Similar Datasets

| S-EPMC5347649 | biostudies-literature
| S-EPMC10045277 | biostudies-literature
| S-EPMC3670259 | biostudies-other
| S-EPMC6317928 | biostudies-literature
| S-EPMC10934655 | biostudies-literature
| S-EPMC5034322 | biostudies-literature
| S-EPMC1890554 | biostudies-literature
| S-EPMC7074527 | biostudies-literature
| S-EPMC4205216 | biostudies-literature
| S-EPMC4058166 | biostudies-literature